Complimentary CME Dinner: Oncology Innovations: Applying the Latest Evidence in Extensive-Stage Small Cell Lung Cancer Care
Ruth's Chris Steak House
131 2nd Avenue North
St. Petersburg, FL 33701
Wednesday, January 28, 2026 at 7:00pm ET - 8:15pm ET
Add this event to your calendar
Info
Topic
For decades, treatment outcomes for small cell lung cancer (SCLC) have remained generally poor. But that’s now changing. New treatment agents and combinations are showing promising results, including improving survival. Join us for a complimentary dinner and CME as our experts discuss the latest efficacy and safety data from clinical trials of newly approved and emerging therapies and new therapeutic combinations.
Credits Offered
This event offers
1.25 contact hours
to attendees.
Accreditation Info:
ANCC.
Additional Information
Learning Objectives:
- Assess efficacy and survival data from recent clinical trials supporting the use of new therapies and new therapeutic combinations in patients with ES-SCLC.
- Design strategies to monitor for and manage adverse events associated with novel combination regimens and new and emerging therapies in ES-SCLC.
Target Audience:
All members of the community oncology care team including medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other HCPs involved in the care of patients with SCLC
Educational Objectives
Upon completion of this activity, participants should be able to:
- Assess efficacy and survival data from recent clinical trials supporting the use of new therapies and new therapeutic combinations in patients with ES-SCLC.
- Design strategies to monitor for and manage adverse events associated with novel combination regimens and new and emerging therapies in ES-SCLC.
Speakers
Associate Member, Department of Thoracic Oncology
Associate Professor, Department of Oncologic Sciences, University of South Florida
Clinical Research Medical Director, Department of Thoracic Oncology
Moffitt Cancer Center, Tampa, Florida
Dr. Sonam Puri is a thoracic medical oncologist and Associate Member at Moffitt Cancer Center, where she serves as Clinical Research Medical Director for Thoracic Oncology and solid tumor lead for the innovative T-cell engager inpatient service (SONIC). Dr. Puri plays active roles in shaping national guidelines as Chair of the ASCO Living Guidelines for Stage IV NSCLC and Deputy Chair of the IASLC Membership Committee. Her research integrates biomarker-driven trial design with translational collaborations, aiming to accelerate the development of novel therapies and improve patient care.
Associate Professor of Medicine Director, Thoracic Oncology Head, Developmental Therapeutics Lombardi Comprehensive Cancer Center Georgetown University, Washington, DC
Dr. Stephen V. Liu, MD, is a thoracic medical oncologist and the Chief of the Division of Hematology & Oncology at Georgetown University. He is an Associate Professor of Medicine at Georgetown University at Georgetown University School of Medicine. He is the Head of Developmental Therapeutics at the Georgetown University Lombardi Comprehensive Cancer Center. He is also co-host of the official IASLC podcast, Lung Cancer Considered. Dr. Liu completed medical training at the University of Pennsylvania and hematology and oncology fellowship at the University of Southern California. He has been on the Georgetown faculty since 2013.